Moh’d Khushman, MD, associate professor, Kirklin Clinic of the University of Alabama (UAB) Hospital, UAB Medicine, discusses best practices in the management of gastrointestinal (GI) cancers.

Molecular profiling is critical for all patients with advanced pancreatic cancer because the results could inform optimal treatment selection in this population, Khushman explains.

In hepatocellular carcinoma (HCC), eligible patients should receive frontline atezolizumab (Tecentriq) plus bevacizumab (Avastin), which is the standard of care, Khushman says.

Finally, patients with gastric/gastroesophageal junction or esophageal adenocarcinoma should receive chemoimmunotherapy in the frontline setting, particularly if they have a PD-L1 combined positive score of at least 5, Khushman concludes.

Videos

Moh’d Khushman, MD, discusses best practices in the management of gastrointestinal cancers.  



Moh’d Khushman, MD

Articles

Dr. Khushman on Best Practices in the Management of GI Cancers